P3, N=238, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026

FOLR1 is overexpressed in a large percentage of low-grade serous ovarian cancers. Mirvetuximab soravtansine may represent a novel treatment option for low-grade serous ovarian cancer patients progressing after standard treatment modalities. Clinical trials with mirvetuximab soravtansine in FOLR1-positive low-grade serous ovarian cancers are warranted.

P2, N=39, Active, not recruiting, University of Rochester | Recruiting --> Active, not recruiting

Enfortumab vedotin, a Nectin-4 targeting ADC, is now the first line therapy of choice in combination with pembrolizumab. Erdafitinib, a pan FGFR1-4 inhibitor, is approved for patients with susceptible FGFR3 alterations...We propose strategies for overcoming resistance including combination strategies, tumor microenvironment modification, and drug structure modification to maximize efficacy. The progress to date in mUC has been remarkable, but there is still significant work to do in this deadly disease and this review highlights the gap between current available therapeutics and cure that so desperately needs to be closed.

P1/2, N=428, Not yet recruiting, Astellas Pharma Global Development, Inc.

P3, N=500, Not yet recruiting, PrECOG, LLC.

P3, N=560, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.

P1, N=227, Terminated, Mythic Therapeutics | Trial completion date: Dec 2027 --> Nov 2025 | Recruiting --> Terminated; Business decision

P2, N=60, Not yet recruiting, GlaxoSmithKline | Trial completion date: Oct 2031 --> Feb 2032 | Initiation date: Dec 2025 --> Mar 2026 | Trial primary completion date: Apr 2027 --> Aug 2027

P2, N=37, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

Emerging evidence indicates that sequential ADC use can be effective despite some cross-resistance, especially when distinct payload mechanisms are employed. Clinical use should consider payload type, timing, and breast cancer subtype, but toxicities remain critical for decision-making. Research providing insights into resistance mechanisms and biomarkers is needed for personalized approaches.

The combination of mebendazole and gefitinib effectively suppresses tumor cell viability and modulates key pathways involved in cancer progression. By targeting cytoskeletal integrity and EGFR signaling, it may disrupt cytokine and tumor-microenvironment interactions, supporting further exploration as a strategy to overcome resistance in lung and breast cancers.